Allarity Therapeutics Files 8-K

Ticker: ALLR · Form: 8-K · Filed: Mar 4, 2025 · CIK: 1860657

Sentiment: neutral

Topics: corporate-update, filing

Related Tickers: ALLR

TL;DR

ALLARITY THERAPEUTICS (ALLR) FILED AN 8-K ON 3/4/25, UPDATING ITS ADDRESS.

AI Summary

On March 3, 2025, Allarity Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 24 School Street, 2nd Floor, Boston, MA 02108. The report was filed on March 4, 2025, and pertains to events occurring on March 3, 2025.

Why It Matters

This filing provides an update on the company's operational status and location, which is important for investors and stakeholders to track corporate developments.

Risk Assessment

Risk Level: low — This filing is a routine corporate update and does not contain significant financial or strategic information that would immediately impact risk.

Key Players & Entities

FAQ

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is March 3, 2025.

What is the principal executive office address for Allarity Therapeutics, Inc.?

The principal executive office address is 24 School Street, 2nd Floor, Boston, MA 02108.

When was this 8-K filing submitted to the SEC?

This 8-K filing was submitted on March 4, 2025.

What is the Commission File Number for Allarity Therapeutics, Inc.?

The Commission File Number for Allarity Therapeutics, Inc. is 001-41160.

What is the Standard Industrial Classification code for Allarity Therapeutics, Inc.?

The Standard Industrial Classification code for Allarity Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 4, 2025 regarding Allarity Therapeutics, Inc. (ALLR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing